VigiLanz Recognized for High Customer Retention, Innovation in KLAS 2019 Infection Control Report

MINNEAPOLIS – March 14, 2019 – VigiLanz, a clinical surveillance company, has been featured in the Infection Control 2019 Report from KLAS Research, released today. The report aggregates and analyzes interviews from thousands of healthcare professionals about the products and services their organizations use.

In the report, KLAS characterizes VigiLanz as a market leader for its high customer retention and innovative technology additions, such as active alerting, in its Dynamic Infection Control Monitor product. VigiLanz is also recognized for providing advanced automation and predictive analytics, two capabilities KLAS identified as highly desired by the market.

“Before we had [VigiLanz’s] Dynamic Infection Control Monitor, I did everything with manual data extraction,” said one anonymized user in the report. “I would have to run about 12 different reports to even get a list of patients to perform surveillance on, and I would need another six reports to get all the communicable disease reporting. [The] Dynamic Infection Control Monitor has made my job so much easier. It is a lot more efficient. I can easily get my patient list and go through it.”

Another anonymized user said, “We consider VigiLanz to be the leader in surveillance because of the flexibility of what we can do with the surveillance.”

VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with EMR systems. Its automatic exception-based alert system continuously surveils all patient records to alert decision makers in real time of potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“We understand how critical an infection prevention product is for patient outcomes and hospitals’ bottom lines, and we’re dedicated to the ongoing innovation that ensures we continue delivering what patients and the market needs,” said David Goldsteen, MD, CEO of VigiLanz. “In general, healthcare executives say infection prevention is one of the top five uses of clinical surveillance technology,[1] and it has rapidly become a critical component of quality patient care.”

The other top uses of clinical surveillance technology, according to healthcare executives, are:

1) Identifying adverse drug events
2) Promoting antimicrobial stewardship
3) Patient safety alerting
4) Managing readmissions

In addition to being a leader in this report, KLAS recognized VigiLanz in the 2019 Best in KLAS report, earning 2019 Category Leader designations for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EMR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

[1] Market Report: Clinical Surveillance: The Next Step in Value-Based Care. Feb. 2019. VigiLanz.

IllumiCare and VigiLanz Partner to Help Pharmacists and Clinicians Advance Antimicrobial Stewardship

Houston Methodist Sugar Land Hospital first in country to launch new point-of-care alert solution with pharmacist-only rollout.

BIRMINGHAM, HOUSTON, & MINNEAPOLIS – February 6, 2018 – The CDC estimates that 20 to 50 percent of antibiotics prescribed in U.S. acute-care hospitals are unnecessary or inappropriate. With the need for healthcare systems and federal agencies to increase their focus on antibiotic stewardship, both providers and pharmacists play a vital role in monitoring safe and appropriate use. Today, VigiLanz, a clinical surveillance company, and IllumiCare, a leading provider of point-of-care technology, announce a partnership to increase visibility within providers’ and pharmacists’ normal workflows around antimicrobial therapy monitoring.

IllumiCare’s Smart Ribbon® is an EMR-agnostic, non-intrusive ribbon of information that hovers over the EMR and provides patient-specific information such as the costs and risks of medications and tests, opioid exposures, and more. The Smart Ribbon displays VigiLanz’s Antimicrobial Stewardship Solution in a more visible, convenient and accessible place in the EMR when the provider or pharmacist is making care decisions. With this ability to respond to context in real-time, the Smart Ribbon only delivers notifications on issues or opportunities that busy clinicians and pharmacists can personally act on. This increases engagement with the VigiLanz insights and saves pharmacists the time and energy often spent tracking down a clinical counterpart to resolve an activation that’s halting the workflow.

“One key element to promoting antimicrobial stewardship is making sure the information is easily accessible to the right clinician or pharmacist when they need it most,” said GT LaBorde, CEO of IllumiCare. “VigiLanz provides real-time information related to safe antibiotic use that can reduce overprescribing or inappropriate prescribing and ultimately, lower costs. By making this information not only easier to see and more actionable, but also appropriately tailored to the person taking the action, antimicrobial stewardship efforts will be more successful.”

Houston Methodist Sugar Land Hospital is the first health system to deploy the VigiLanz clinical surveillance alerts within IllumiCare’s Smart Ribbon. Pharmacists can choose to engage with VigiLanz activations by viewing them, marking them as necessary and providing comments, all within their current workflow in the EMR. One of the most important activations is the visibility of drug-bug mismatches, in which the antimicrobial a patient receives is not adequate for the microbiological organism presumed to be causing the clinical infection. Additionally, the VigiLanz alerts highlight broad antimicrobial use, de-escalation opportunities, and conversion opportunities to move the patient to an antibiotic that has equal efficacy but is less expensive, such as from IV drugs to oral medications.

“Having actionable insights into antimicrobial use is critical; being able to put those insights in front of clinicians and pharmacists at the point of care is industry-leading,” said David Goldsteen, MD, CEO of VigiLanz. “We’re thrilled to be partnering with IllumiCare to deliver our trusted clinical surveillance insights through their Smart Ribbon to those who take action, ensuring safe and appropriate antimicrobial use.”

For more information, visit Illumicare at www.illumicare.com and VigiLanz at www.vigilanzcorp.com

VigiLanz Ranked No. 1 by KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance

MINNEAPOLIS – Jan. 31, 2019 – VigiLanz, a clinical surveillance company, today announced that it has earned 2019 Category Leader designations from KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance.

This is the second year VigiLanz has earned the No. 1 distinction for multiple categories. The company previously achieved Category Leader status in 2018 for Infection Control and Monitoring and Pharmacy Surveillance. Antimicrobial Stewardship is a new KLAS category for 2019.

Three VigiLanz products were recognized in the “2019 Best in KLAS: Software and Services” report, released on January 31:

VigiLanz Dynamic Infection Control Monitor

Earning a score of 90.6, the Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Its automatic exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

VigiLanz Dynamic PharmacoVigilance

Earning a score of 93.0, Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

VigiLanz Antimicrobial Stewardship

Earning a score of 94.6, the Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and provides direct reporting to the Centers for Disease Control’s National Healthcare Safety Network.

“It’s an honor to be recognized by KLAS as a leader in multiple categories for the second time, validating the confidence and trust we know our customers have in our clinical surveillance products,” said VigiLanz Chairman and CEO David Goldsteen, MD. “KLAS’ global reputation for accurately and impartially measuring vendor performance is an unparalleled channel for customer feedback – something we find invaluable to our culture of continued innovation. We look forward to continuing to provide industry-leading solutions to hospitals across the country that improve the safety and quality of patient outcomes.”

The KLAS Category Leader designation is awarded to vendors that lead select market segments in which at least two products meet a minimum number of KLAS Konfidence reviews. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

VigiLanz and Cincinnati Children’s Collaborate to Commercialize a Real-Time Solution to Minimize Acute Kidney Injury in Pediatrics

MINNEAPOLIS & CINCINNATI – (November 29, 2018) – VigiLanz and Cincinnati Children’s Hospital Medical Center today announced a collaboration that leverages Cincinnati Children’s ground-breaking research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for Acute Kidney Injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Dr. Stuart L. Goldstein, MD, FAAP, FNKF, Director of the Center for Acute Care Nephrology and primary researcher on NINJA.  “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially-available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates a time-consuming manual screening process that includes evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye, and recent renal testing. For medications, manual screening is limited to the last 24 hours, while the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data, and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

“By expanding awareness of the extensive research conducted by Cincinnati Children’s, this partnership will help drive improvements in pediatric AKI outcomes,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Those improvements can be realized quickly, too, as the NINJA dashboard is not just a concept but rather a tangible solution now available to any hospital interested in limiting AKI associated with nephrotoxic drugs.”

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

Interoperability in Real Life: Practical Ways to Leverage APIs & Transform Healthcare

Interoperability between EMRs and other applications is a key challenge in healthcare today. Application Programming Interfaces (APIs) have transformed interoperability in other industries and now healthcare, too, is increasingly relying on them to solve important clinical and business problems. VigiLanz recently co-hosted a panel discussion on the topic, with one of its partners, Sansoro Health, which featured leaders from a diverse group of healthcare organizations, who shared how they use proven API solutions to successfully address complex, real-world clinical, operational and workflow challenges.

Although the three panelists were at different stages of their journey in leveraging APIs to provide better healthcare solutions, more rapidly and at lower cost, all recognize that legacy technology does not meet their needs for integration with EMRs and data liquidity.

The Longest-Established API User

As moderator of the panel discussion, David Levin, MD, Chief Medical Officer of Sansoro Health and former CMIO of Cleveland Clinic Health System, explained it’s vital to have bi-directional data flow back into EMRs to save clinicians from double documenting. It’s an issue that Peter Chang, MD, Chief Medical Information Officer, Tampa General Hospital, faced, until he implemented Sansoro Health’s Emissary® API solution to deliver efficient, real-time read-and-write EMR interaction across complete patient demographics and clinical data. The longest established API user of the group, Dr. Chang spoke about how his hospital leverages APIs to focus solely on their application and not get disrupted on the integration. Tampa General Hospital can now integrate in a matter of days across EMRs, sourcing all the data its clinicians need.

The Middle Stage of the Middleware Journey

Adam Klass, Chief Technology Officer of VigiLanz, at the middle stage of the middleware journey, spoke on how APIs reduce barriers to EMR integration and can be rapidly deployed to provide robust, real-time interoperability between complex applications. To help healthcare providers deliver real-time results and  improve interoperability, he described how medical facilities today require a services-oriented architecture and API. The API must enable efficient aggregation, interaction and exchange of disparate data throughout the health care enterprise and across any of its software technologies, including EMRs and third-party vendors.

Klass, one of the company’s original founders in 2001, outlined the company’s mission of providing real-time clinical decision support to its customers by helping with all manners of manual data collection processes, using data and real-time rules engines. From pharmacy surveillance and predictive models to antimicrobial stewardship and other clinical use cases, the company relies on receiving EMR data in a timely manner. VigiLanz has always sought to answer the question of how to extract data from an EMR. It wasn’t rocket science, in Klass’ words, and yet it was challenging to collect the same data from every hospital in every EMR, in a way that enabled customers to have an intimate understanding of provider behavior through benchmarking. A creative solution was needed.

It’s one reason VigiLanz partnered with Sansoro Health to develop its VigiLanz Connect solution, which plugs into an organization’s EMR in less than one week for hospital IT-lite integration. Traditional integration methods are often customized for each installation, require regular maintenance and cannot be reused. Using a standard set of population-based APIs that facilitate seamless, real-time, bi-directional data flow, VigiLanz Connect normalizes data faster—and empowers clinicians to make an impact sooner. It plugs in once to deliver standardized, interchangeable APIs for seamless integration across all data sources. VigiLanz Connect has now been successfully deployed at several hospitals.

Exploring the Advantages to APIs

Matthew Cunningham, Executive Vice President of eviCore, described how his company is comprised of more than one thousand doctors and nurses in its ranks, so it needs a robust, flexible platform to identify and distribute the precise data and analytics to make informed, individual-based decisions across the 100 million lives it manages. With an understanding for the types of clinical and business problems that can be addressed with API technology, eviCore has begun to explore the advantages of commercially available APIs, like Sansoro Health’s Emissary platform.

Plug-and-play EMR integration is a reality today. Within days, hospital organizations are up and running with a standard set of APIs that work the same across EMRs. By leveraging middleware, organizations only code their application once for seamless integration across all data sources. This eliminates the need to build traditional custom interfaces for each EMR, saving significant time, resources and reducing costs – for clinicians, the hospital IT department and third-party solutions.

Connexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient Safety

BOULDER, CO & TORONTO, ON – (February 28, 2018) – Connexall and VigiLanz, both named Category Leaders in the 2018 Best in KLAS awards, have teamed up to deliver time-sensitive information related to antimicrobial stewardship (AMS) to increase patient safety and improve outcomes at hospitals.

The VigiLanz AMS platform aggregates information from physician order entries, laboratory and pathology reports, and the EHR to provide continuous surveillance of patients.  Connexall integrates with VigiLanz and the EHR to intelligently route data quickly and reliably to the assigned care team for the affected patient. This guides the care team to ensure safe and appropriate use of antibiotics.

“AMS has emerged as a central component of highly effective care quality and safety strategies, and success requires the ability to rapidly transform data into action,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “This partnership between VigiLanz and Connexall does just that, providing our customers with a robust AMS solution that leverages the power of two KLAS category leaders to drive improved patient outcomes.”

“Connexall is delighted to partner with VigiLanz to enhance antimicrobial stewardship programs for the benefit of patients.” stated David Tavares, GlobeStar/Connexall CEO.  “Our intelligent routing capabilities ensure that the assigned care team is notified promptly and reliably to deliver the care the patients require.” continued Tavares.

To learn more about this progressive solution, please visit VigiLanz at Booth #2674 and Connexall at Booth #8105 at HIMSS18.

About Connexall

Connexall, ranked number one and named Category Leader in the 2015/2016, 2017, and 2018 Best in KLAS awards, is an enterprise-grade event management and control platform that delivers hospital-wide interoperability to people, systems, tasks, and devices.  Its capabilities act as a backbone for clinical workflow, communicating the right information to the right person, at the right time, on the right device. Based on more than 20 years of R&D efforts, the Class II medical device software is completely vendor-neutral and device-independent. Connexall has offices in Canada, the United States, Brazil, Portugal and Hong Kong and works with well over a thousand of the world’s most renowned and progressive hospitals and health systems.  For more information please visit www.connexall.com.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Ranked #1 in Best in KLAS Report for Infection Control and Clinical Decision Support-Surveillance Categories

MINNEAPOLIS – (January 31, 2018) – VigiLanz, a digital healthcare intelligence firm, announced today that it has earned 2018 Category Leader designations for Infection Control and Clinical Decision Support-Surveillance in the 2018 Best in KLAS: Software and Services report. These mark the second and third KLAS honors in the past year for VigiLanz, which also achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report for its platform, customer partnerships, and dedication to customer service and support.

In the “2018 Best in KLAS: Software and Services,” report, released on January 30, VigiLanz’s Dynamic Infection Control Monitor  product garnered a score of 90.3 while its Dynamic PharmacoVigilance product earned an 89.9.

The Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence. Rankings are based on customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment solutions.

Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Via an automatic exception-based alert system, all patient records are under continuous surveillance to alert decision makers in real time to potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of rule engines that can be customized for each hospital.

Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, the system automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“VigiLanz is honored to see our solutions recognized as Category Leaders, particularly as healthcare professionals are the engine that drives KLAS’ impartial research on the software and services used by providers worldwide,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Following upon VigiLanz’ recognition by KLAS in 2017 for our Antimicrobial Stewardship products, these additional designations further validate our reputation among clinicians and administrators alike as a company that offers the best, top-performing solutions in the industry.”

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Unveils Automated Safety Event Detection and Reporting

MINNEAPOLIS – (December 6, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today the launch of a state-of-the-art automation solution that helps hospitals optimize safety event reporting and enhance compliance with accreditation requirements. VigiLanz® Dynamic Safety Surveillance transforms clinical data into actionable intelligence, empowering hospitals to achieve greater risk reduction through automated safety event detection, management and analytics.

Patient falls and adverse drug events are the most common safety events, which also include surgical errors, wrong blood products, injuries to employees and visitors, and workplace violence. As many as 440,000 people die annually from hospital errors, injuries, accidents and infections. To help combat these issues, The Joint Commission made safety event reporting a requirement for accreditation, which uses the information to improve quality and safety of its hospitals.

Despite the importance of safety event reporting, hospitals are confronted with several barriers that prevent a comprehensive accounting of adverse occurrences. These include:

  • Limited information on the event
  • The time required to complete incident forms
  • A lack of urgency to report events considered too minor
  • Confusion over reporting responsibilities

VigiLanz Dynamic Safety Surveillance overcomes these obstacles by automating the common approaches to managing, reporting and detecting safety events—including capturing information on serious unsafe conditions and resulting adverse events that previously went unreported.

“Those unreported incidents have the potential to do significant long-term harm, as even minor events can escalate into serious, even deadly, situations,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Over-reliance on humans to identify and report safety events exposes hospitals to repercussions ranging from loss of payment for ‘never events’ and damaged reputations to patient grievances and lawsuits. VigiLanz Dynamic Safety Surveillance mitigates those risks with a powerful set of monitoring and reporting tools that supplement human actions for comprehensive reporting.”

VigiLanz Dynamic Safety Surveillance integrates clinical data from multiple sources with comprehensive detection and investigation tools, automated escalation, and a full library of analytical and reporting tools into a single solution that:

  • Accelerates the event reporting life cycle through customized workflows
  • Converts health data automatically into uniform intelligence for more complete reporting and event detection
  • Provides comprehensive tools for efficient analysis
  • Generates state of the art dashboards for real-time monitoring

“The business of safety reporting starts with an organizational culture that embraces reporting all safety events,” said Dr. Goldsteen. “VigLanz Dynamic Safety Surveillance takes it to the next level with a tool that facilitates communications about all safety events, including those that might otherwise go unreported.”

For a demonstration of its new Safety Surveillance solution, visit VigiLanz in Booth #212 at the IHI National Forum, taking place Dec. 10-13 in Orlando, Fla.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Integrates Infectious Disease Content from Sanford Guide

MINNEAPOLIS – (November 29, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that users of its market-leading clinical intelligence platform now have direct access to the industry’s top digital infectious disease content. Integrating content from The Sanford Guide lets clinicians and pharmacists take the critical next step in the antimicrobial de-escalation process by leveraging peer-reviewed recommendations on the latest treatments—without having to exit the VigiLanz workflow.

Through its exclusive partnership with Sanford Guide, the most trusted name in the treatment of infectious disease, VigiLanz clients can access the full suite of digital infection disease content and associate it with specific rules. Users can then search comprehensive coverage of the latest clinician-designed treatment options for infectious diseases, syndromes, and pathogens from within the VigiLanz system, driving improved patient outcomes.

“The value of this partnership to our clients extends beyond their VigiLanz users to include any clinician or pharmacist in need of the actionable treatment recommendations, tailored for use in clinical scenarios, from anywhere across the enterprise,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA.

Noting that the company’s antimicrobial stewardship platform recently achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research, Goldsteen added, “The Sanford Guide’s exceptional content and clinical guidance are the perfect complement to our nationally-recognized platform, advancing care quality and patient safety through industry-leading guidance on the treatment of infectious diseases.”

The VigiLanz clinical intelligence platform leverages real-time monitoring of thousands of patient care data elements to help improve medication safety, antimicrobial stewardship, infection prevention, quality and care management, and patient safety. Its state-of-the-art rules engine analyzes that data and pushes alerts to clinicians at the point of care when interventions and other actions are necessary, driving significant improvements in safety, efficiency, performance, and reimbursement.

Trusted by clinicians in more than 100 countries, The Sanford Guide is optimized to minimize time-to-answer while providing comprehensive guidance at the point of care. With continually updated information based on the latest available evidence, focused anti-infective drug information, interactive dosing tables, and extensive links to references and related resources, The Sanford Guide provides actionable guidance that is accessible, concise, and reliable.

“By integrating The Sanford Guide’s trusted clinical treatment recommendations with its top-rated clinical surveillance tools, VigiLanz is helping hospital and health systems take their approach to infectious disease and antimicrobial stewardship to the next level,” said Sanford Guide CEO and Managing Editor Jeb Sanford.

For more information on the integrated VigiLanz-Sanford Guide solution, visit VigiLanz in booth #1641 during the ASHP Midyear Clinical Meeting And Exhibition, taking place Dec. 3-7 in Orlando, Fla.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.